Diagnosis and treatment of portal hypertension

Hepatology Research

Volumn 39, Issue 10, 2009, Pages 1039-1043

  Segawa, Makoto ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotension II receptor type 1 blockers; Anti fibrotic therapy; Autologous bone marrow cells infusion; Balloon occluded transvenous obliteration; Partial splenic embolization; Portal hypertension

Indexed keywords

CANDESARTAN; IOPAMIDOL; IRBESARTAN; LOSARTAN; OLMESARTAN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; ARTIFICIAL EMBOLISM; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BALLOON OCCLUSION; BLOOD VESSEL OCCLUSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ECHOGRAPHY; ELASTOGRAPHY; ENDOSCOPIC SURGERY; ESOPHAGOSCOPY; ESOPHAGUS VARICES; HEPATITIS C; HUMAN; HYPERSPLENISM; JAPAN; LIVER ANGIOGRAPHY; LIVER CIRCULATION; LIVER FIBROSIS; MEDICAL DECISION MAKING; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INVASIVE MEASUREMENT; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PREDICTION; PRESSURE GRADIENT; PRIORITY JOURNAL; TREATMENT OUTCOME; VEIN LIGATION;

EID: 73849116206     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00554.x     Document Type: Article

References (44)

1. The Japan Society for Portal Hypertension. [The general rules for study of portal hypertension, 2nd edn.] Tokyo: Kanehara, 2004; 3-11. (In Japanese.)
2. Garcia-tsao G, Groszmann RJ, Fisher RL et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5: 419-24.
3. Viallet A, Marleau D, Huet M et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975; 69: 1297-300.
4. Feu F, Garcia-Pagan JC, Bosch J et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-9.
5. Carrión JA, Navasa M, Bosch J et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-8.
6. Vizzutti F, Arena U, Romanelli RG et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45: 1290-7.
7. Kazemi F, Kettaneh A, N'kontchou G et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45: 230-5.
8. Foucher J, Chanteloup E, Vergniol J et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8.
9. Matsumoto A, Kitamoto M, Imamura M et al. Threedimensional portography using multislice helical CT is clinically useful for management og gastric fundic varices. Am J Roentgenol 2001; 176: 899-905.
10. Willmann JK, Weishaupt D, Bohm T et al. Detection of submucosal gastric fundal varices with multi-detector row CT angiography. Gut 2004; 52: 886-92.
11. De Franchis R. Non invasive diagnosis of esophageal varices: is it feasible?AmJ Gastroenterol 2006; 101: 2520-22.
12. Thabut D, Trabut JB, Massard J et al. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver Int 2006; 26: 271-8.
13. Giannini EG, Botta F, Borro P et al. Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow up. Dig Liver Dis 2005; 37: 779-85.
14. Kanagawa H, Mima S, Mima S, Kouyama H et al. Treatment of gastric varices by balloon occluded retrograde transvenous obliteration. J Gastroenterol Hepatol 1996; 11: 51-8.
15. Akahane T, Iwasaki T, Kobayashi N et al. Changes in liver function parameters after occlusion of gastrorenal shunts with balloon-occluded retrograde transvenous obliteration. Am J Gastroenterol 1997; 92: 1026-30.
16. Kiyosue H, Matsumoto S, Onishi R et al. Balloon-occluded retrograde transvenous obliteration (B-RTO) for gastric varices: therapeutic results and problems. Nippon Acta radiologica 1999; 59: 12-19. (in Japanese.)
17. Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Inrev Radiol 2001; 12: 327-36.
18. Ninoi T, Nishida N, Kaminou T et al. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long term follow-up in78 patients. AJR 2005; 184: 1340-6.
19. Chikamori F, Kuniyoshi N, Shibuya S et al. Eight years of experience with transjugular retrograde obliteraion for gastric varices with gastrorenal shunts. Surgery 2001; 129: 414-20.
20. Arai H, Abe T, Takagi H et al. Efficacy of balloon-occluded retrograde transvenous obliteration, percutaneous transhepatic obliteration and combined techniques for the management of gastric fundal varices. World J Gastroenterol 2006; 12: 3866-73.
21. Hiraga N, Aikata H, Takaki S et al. The long-term outcome of patients with bleeding gastric varices after balloonoccluded retrograde transvenous obliteration. J Gastroenterol 2007; 42: 663-72.
22. Cho SK, Shin SW, Lee IH et al. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients. AJR 2007; 189: 365- 72.
23. Yoshida H, Mamada Y, Taniai N et al. Partial splenic embolization. Hepatol Res 2008; 38: 225-33.
24. Koconis KG, Singh H, Soares G et al. Partial embolization in the treatment of patients with portal hypertension: a review of the English language literature. J Vasc Interv Radiol 2007; 18: 463-81.
25. Tajiri T, Onda M, Yoshida H et al. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology 2002; 49: 1445-8.
26. Ohmoto K, Yamamoto S. Prevention of variceal recurrence, bleeding, and death in cirrhosis patients with hypersplenism, especially those with severe thrombocytopenia. Hepatogastroenterology 2003; 50: 1766-9.
27. Shimizu T, Onda M, Tajiri T et al. Bleeding portalhypertensive gastropathy managed successfully by partial splenic embolization. Hepatogastroenterology 2002; 49: 947-9.
28. Foruny JR, Blazquez J, Moreno A et al. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol 2005; 17: 1157-64.
29. Huang JH, Gao F, Gu YK et al. Combined treatment of hepatocelluar carcinoma with partial embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007; 13 (48): 6593-7.
30. Ramon B, Pere G, Josep MN et al. Angiotensin II induced contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
31. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29: 1149-56.
32. Schepke M, Werner E, Biecker E et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001; 121: 389-95.
33. Debernardi-Venon W, Martini S, Biasi F et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-33.
34. Hidaka H, Kokubu S, Nakazawa T et al. New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. Hepatol Res 2007; 37: 1011-17.
35. Gonzalez-Abraldes J, Albillos A, Banares A et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382-8.
36. Yoshiji H, Kuriyama S, Yoshiji J et al. Angiotensin-II type 1 receptor interaction is a major regulator for fibrosis development in rats. Hepatology 2001; 34: 745-50.
37. Jin H, Yamamoto N, Uchida K et al. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino aciddeficient diet. Biochem Biophys Res Commun 2007; 364: 801-7.
38. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
39. Rincon D, Ripoll C, Iacono OL et al. Antivairal therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101: 2269-74.
40. Theise ND, Nimmakayalu M, Gardner R et al. Liver from bone marrow in humans. Hepatology 2000; 32: 11-16.
41. Alison MR, Poulsom R, Jeffery R et al. Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406: 257.
42. Terai S, Yamamoto N, Omori K et al. A new cell therapy using bone marrow cells to repair damaged liver. J Gastroenterol 2002; 37 (Suppl. XIV): 162-3.
43. Sakaida I, Terai S, Yamamoto N et al. Transplantation of bone marrow cell reduces CCl4-induced liver fibrosis in mice. Hepatology 2004; 40: 1304-11.
44. Terai S, Ishikawa T, Omori K et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006; 24: 2292- 8.